Listed

Adaptimmune Therapeutics PLC

ADAPYOTCCIK 1621227HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$13.7m, Q2 FY2025
Operating income−$30.3m, Q2 FY2025
Net income−$30.3m, Q2 FY2025
Adaptimmune Therapeutics PLC, income statement, quarterly
Line itemUnitQ3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30
Revenue$m7.0Revenue, Q3 FY2022, three months to 2022-09-30$7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure11.0Revenue, Q4 FY2022, three months to 2022-12-31$11.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure47.6Revenue, Q1 FY2023, three months to 2023-03-31$47.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure5.1Revenue, Q2 FY2023, three months to 2023-06-30$5.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure7.3Revenue, Q3 FY2023, three months to 2023-09-30$7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure0.2Revenue, Q4 FY2023, three months to 2023-12-31$231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure5.7Revenue, Q1 FY2024, three months to 2024-03-31$5.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure128Revenue, Q2 FY2024, three months to 2024-06-30$128.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure40.9Revenue, Q3 FY2024, three months to 2024-09-30$40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure3.2Revenue, Q4 FY2024, three months to 2024-12-31$3.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure7.3Revenue, Q1 FY2025, three months to 2025-03-31$7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure13.7Revenue, Q2 FY2025, three months to 2025-06-30$13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.9Cost of revenue, Q1 FY2025, three months to 2025-03-31$879.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure2.5Cost of revenue, Q2 FY2025, three months to 2025-06-30$2.5m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Research and development$m33.2Research and development, Q3 FY2022, three months to 2022-09-30$33.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure23.1Research and development, Q4 FY2022, three months to 2022-12-31$23.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure25.5Research and development, Q1 FY2023, three months to 2023-03-31$25.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure30.0Research and development, Q2 FY2023, three months to 2023-06-30$30.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure37.8Research and development, Q3 FY2023, three months to 2023-09-30$37.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure33.2Research and development, Q4 FY2023, three months to 2023-12-31$33.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure35.2Research and development, Q1 FY2024, three months to 2024-03-31$35.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure40.4Research and development, Q2 FY2024, three months to 2024-06-30$40.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure34.3Research and development, Q3 FY2024, three months to 2024-09-30$34.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure39.1Research and development, Q4 FY2024, three months to 2024-12-31$39.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure28.9Research and development, Q1 FY2025, three months to 2025-03-31$28.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure23.0Research and development, Q2 FY2025, three months to 2025-06-30$23.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Selling, general and administrative$mnot reportednot reportednot reportednot reported16.2Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$16.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure16.9Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$16.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure19.7Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$19.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure19.1Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$19.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure21.3Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$21.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure27.2Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$27.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure23.3Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$23.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure18.5Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$18.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Operating income$m(43.0)Operating income, Q3 FY2022, three months to 2022-09-30−$43.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure(27.2)Operating income, Q4 FY2022, three months to 2022-12-31−$27.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure1.7Operating income, Q1 FY2023, three months to 2023-03-31$1.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure(44.9)Operating income, Q2 FY2023, three months to 2023-06-30−$44.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure(46.6)Operating income, Q3 FY2023, three months to 2023-09-30−$46.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(49.9)Operating income, Q4 FY2023, three months to 2023-12-31−$49.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(49.3)Operating income, Q1 FY2024, three months to 2024-03-31−$49.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure68.7Operating income, Q2 FY2024, three months to 2024-06-30$68.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(14.7)Operating income, Q3 FY2024, three months to 2024-09-30−$14.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(73.5)Operating income, Q4 FY2024, three months to 2024-12-31−$73.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(45.7)Operating income, Q1 FY2025, three months to 2025-03-31−$45.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(30.3)Operating income, Q2 FY2025, three months to 2025-06-30−$30.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported0.5Interest expense, Q2 FY2024, three months to 2024-06-30$526.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure1.1Interest expense, Q3 FY2024, three months to 2024-09-30$1.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure1.7Interest expense, Q4 FY2024, three months to 2024-12-31$1.7m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure1.9Interest expense, Q1 FY2025, three months to 2025-03-31$1.9m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure1.0Interest expense, Q2 FY2025, three months to 2025-06-30$962.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Income tax$m0.4Income tax, Q3 FY2022, three months to 2022-09-30$399.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure1.0Income tax, Q4 FY2022, three months to 2022-12-31$994.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure0.6Income tax, Q1 FY2023, three months to 2023-03-31$625.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure0.7Income tax, Q2 FY2023, three months to 2023-06-30$680.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure0.7Income tax, Q3 FY2023, three months to 2023-09-30$687.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(0.7)Income tax, Q4 FY2023, three months to 2023-12-31−$656.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure0.5Income tax, Q1 FY2024, three months to 2024-03-31$526.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure0.5Income tax, Q2 FY2024, three months to 2024-06-30$526.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure0.8Income tax, Q3 FY2024, three months to 2024-09-30$831.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure1.7Income tax, Q4 FY2024, three months to 2024-12-31$1.7m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure0.6Income tax, Q1 FY2025, three months to 2025-03-31$575.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure0.6Income tax, Q2 FY2025, three months to 2025-06-30$612.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Net income$m(41.4)Net income, Q3 FY2022, three months to 2022-09-30−$41.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure(29.3)Net income, Q4 FY2022, three months to 2022-12-31−$29.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure1.0Net income, Q1 FY2023, three months to 2023-03-31$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(21.4)Net income, Q2 FY2023, three months to 2023-06-30−$21.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(45.6)Net income, Q3 FY2023, three months to 2023-09-30−$45.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(47.9)Net income, Q4 FY2023, three months to 2023-12-31−$47.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(48.5)Net income, Q1 FY2024, three months to 2024-03-31−$48.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure69.5Net income, Q2 FY2024, three months to 2024-06-30$69.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(17.6)Net income, Q3 FY2024, three months to 2024-09-30−$17.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(74.2)Net income, Q4 FY2024, three months to 2024-12-31−$74.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(47.6)Net income, Q1 FY2025, three months to 2025-03-31−$47.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(30.3)Net income, Q2 FY2025, three months to 2025-06-30−$30.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Diluted EPS$ per share(0.04)Diluted EPS, Q3 FY2022, three months to 2022-09-30−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figurenot reported0.00Diluted EPS, Q1 FY2023, three months to 2023-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure(0.02)Diluted EPS, Q2 FY2023, three months to 2023-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure(0.03)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figurenot reported(0.03)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure0.04Diluted EPS, Q2 FY2024, three months to 2024-06-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(0.01)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figurenot reported(0.03)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(0.02)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Basic EPS$ per share(0.04)Basic EPS, Q3 FY2022, three months to 2022-09-30−$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figurenot reported0.00Basic EPS, Q1 FY2023, three months to 2023-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure(0.02)Basic EPS, Q2 FY2023, three months to 2023-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure(0.03)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figurenot reported(0.03)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure0.05Basic EPS, Q2 FY2024, three months to 2024-06-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(0.01)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figurenot reported(0.03)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(0.02)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure

Balance sheet

Cash and equivalents$26.1m, Q2 FY2025
Long-term debt$25.7m, Q2 FY2025
Shareholders' equity−$71.0m, Q2 FY2025
Adaptimmune Therapeutics PLC, balance sheet, quarterly
Line itemUnitQ3 FY20222022-09-30FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30
Cash and equivalents$m79.0Cash and equivalents, Q3 FY2022, at 2022-09-30$79.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2022-11-08, accession 0001558370-22-016869.Report this figure108Cash and equivalents, FY2022, at 2022-12-31$108.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure120Cash and equivalents, Q1 FY2023, at 2023-03-31$119.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-05-12, accession 0001558370-23-009595.Report this figure77.0Cash and equivalents, Q2 FY2023, at 2023-06-30$77.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-08-09, accession 0001558370-23-014250.Report this figure90.1Cash and equivalents, Q3 FY2023, at 2023-09-30$90.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure144Cash and equivalents, FY2023, at 2023-12-31$144.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure141Cash and equivalents, Q1 FY2024, at 2024-03-31$140.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure212Cash and equivalents, Q2 FY2024, at 2024-06-30$211.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure117Cash and equivalents, Q3 FY2024, at 2024-09-30$116.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure91.1Cash and equivalents, FY2024, at 2024-12-31$91.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure41.1Cash and equivalents, Q1 FY2025, at 2025-03-31$41.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure26.1Cash and equivalents, Q2 FY2025, at 2025-06-30$26.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Current assets$m264Current assets, Q3 FY2022, at 2022-09-30$264.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2022-11-08, accession 0001558370-22-016869.Report this figure255Current assets, FY2022, at 2022-12-31$255.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure214Current assets, Q1 FY2023, at 2023-03-31$213.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-05-12, accession 0001558370-23-009595.Report this figure262Current assets, Q2 FY2023, at 2023-06-30$261.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-08-09, accession 0001558370-23-014250.Report this figure219Current assets, Q3 FY2023, at 2023-09-30$219.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure208Current assets, FY2023, at 2023-12-31$207.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure187Current assets, Q1 FY2024, at 2024-03-31$186.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure254Current assets, Q2 FY2024, at 2024-06-30$253.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure244Current assets, Q3 FY2024, at 2024-09-30$244.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure188Current assets, FY2024, at 2024-12-31$188.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure103Current assets, Q1 FY2025, at 2025-03-31$103.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure78.1Current assets, Q2 FY2025, at 2025-06-30$78.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Total assets$m332Total assets, Q3 FY2022, at 2022-09-30$332.2m. XBRL concept us-gaap:Assets. 10-Q filed 2022-11-08, accession 0001558370-22-016869.Report this figure329Total assets, FY2022, at 2022-12-31$328.9m. XBRL concept us-gaap:Assets. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure288Total assets, Q1 FY2023, at 2023-03-31$288.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-05-12, accession 0001558370-23-009595.Report this figure343Total assets, Q2 FY2023, at 2023-06-30$343.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-08-09, accession 0001558370-23-014250.Report this figure297Total assets, Q3 FY2023, at 2023-09-30$296.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure283Total assets, FY2023, at 2023-12-31$282.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure258Total assets, Q1 FY2024, at 2024-03-31$258.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure322Total assets, Q2 FY2024, at 2024-06-30$321.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure317Total assets, Q3 FY2024, at 2024-09-30$317.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure246Total assets, FY2024, at 2024-12-31$246.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure158Total assets, Q1 FY2025, at 2025-03-31$158.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure131Total assets, Q2 FY2025, at 2025-06-30$130.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Current liabilities$m66.1Current liabilities, Q3 FY2022, at 2022-09-30$66.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2022-11-08, accession 0001558370-22-016869.Report this figure64.5Current liabilities, FY2022, at 2022-12-31$64.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure63.6Current liabilities, Q1 FY2023, at 2023-03-31$63.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-05-12, accession 0001558370-23-009595.Report this figure76.1Current liabilities, Q2 FY2023, at 2023-06-30$76.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-08-09, accession 0001558370-23-014250.Report this figure75.1Current liabilities, Q3 FY2023, at 2023-09-30$75.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure72.8Current liabilities, FY2023, at 2023-12-31$72.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure66.4Current liabilities, Q1 FY2024, at 2024-03-31$66.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure82.1Current liabilities, Q2 FY2024, at 2024-06-30$82.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure63.5Current liabilities, Q3 FY2024, at 2024-09-30$63.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure64.5Current liabilities, FY2024, at 2024-12-31$64.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure51.1Current liabilities, Q1 FY2025, at 2025-03-31$51.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure51.5Current liabilities, Q2 FY2025, at 2025-06-30$51.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Total liabilities$m219Total liabilities, Q3 FY2022, at 2022-09-30$218.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2022-11-08, accession 0001558370-22-016869.Report this figure247Total liabilities, FY2022, at 2022-12-31$247.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure204Total liabilities, Q1 FY2023, at 2023-03-31$204.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-05-12, accession 0001558370-23-009595.Report this figure216Total liabilities, Q2 FY2023, at 2023-06-30$216.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-08-09, accession 0001558370-23-014250.Report this figure209Total liabilities, Q3 FY2023, at 2023-09-30$208.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure243Total liabilities, FY2023, at 2023-12-31$243.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure234Total liabilities, Q1 FY2024, at 2024-03-31$233.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure225Total liabilities, Q2 FY2024, at 2024-06-30$225.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure237Total liabilities, Q3 FY2024, at 2024-09-30$237.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure234Total liabilities, FY2024, at 2024-12-31$234.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure196Total liabilities, Q1 FY2025, at 2025-03-31$195.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure202Total liabilities, Q2 FY2025, at 2025-06-30$201.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported25.0Long-term debt, Q2 FY2024, at 2024-06-30$25.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure49.9Long-term debt, Q3 FY2024, at 2024-09-30$49.9m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure50.2Long-term debt, FY2024, at 2024-12-31$50.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure25.4Long-term debt, Q1 FY2025, at 2025-03-31$25.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure25.7Long-term debt, Q2 FY2025, at 2025-06-30$25.7m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Shareholders' equity$m113Shareholders' equity, Q3 FY2022, at 2022-09-30$113.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure81.9Shareholders' equity, FY2022, at 2022-12-31$81.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure83.9Shareholders' equity, Q1 FY2023, at 2023-03-31$83.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure127Shareholders' equity, Q2 FY2023, at 2023-06-30$126.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure88.1Shareholders' equity, Q3 FY2023, at 2023-09-30$88.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure39.5Shareholders' equity, FY2023, at 2023-12-31$39.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure24.4Shareholders' equity, Q1 FY2024, at 2024-03-31$24.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure96.3Shareholders' equity, Q2 FY2024, at 2024-06-30$96.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure80.0Shareholders' equity, Q3 FY2024, at 2024-09-30$80.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure11.8Shareholders' equity, FY2024, at 2024-12-31$11.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(37.4)Shareholders' equity, Q1 FY2025, at 2025-03-31−$37.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(71.0)Shareholders' equity, Q2 FY2025, at 2025-06-30−$71.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure

Cash flow

Operating cash flow−$34.8m, Q2 FY2025
Capital expenditure$75.0k, Q2 FY2025
Adaptimmune Therapeutics PLC, cash flow, quarterly
Line itemUnitQ3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30
Operating cash flow$m(48.2)Operating cash flow, Q3 FY2022, three months to 2022-09-30−$48.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-11-08, accession 0001558370-23-018265. Derived: 9-month figure less the 6-month figure.Report this figure2.0Operating cash flow, Q4 FY2022, three months to 2022-12-31$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(37.3)Operating cash flow, Q1 FY2023, three months to 2023-03-31−$37.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure(43.8)Operating cash flow, Q2 FY2023, three months to 2023-06-30−$43.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-08-12, accession 0001558370-24-011798. Derived: 6-month figure less the 3-month figure.Report this figure(45.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$45.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Report this figure(14.7)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$14.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(32.0)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$31.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure47.4Operating cash flow, Q2 FY2024, three months to 2024-06-30$47.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Report this figure(54.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$54.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Report this figure(34.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$34.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(66.6)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$66.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(34.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$34.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m10.0Capital expenditure, Q3 FY2022, three months to 2022-09-30$10.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-11-08, accession 0001558370-23-018265. Derived: 9-month figure less the 6-month figure.Report this figure3.4Capital expenditure, Q4 FY2022, three months to 2022-12-31$3.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure2.3Capital expenditure, Q1 FY2023, three months to 2023-03-31$2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure1.2Capital expenditure, Q2 FY2023, three months to 2023-06-30$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-08-12, accession 0001558370-24-011798. Derived: 6-month figure less the 3-month figure.Report this figure0.3Capital expenditure, Q3 FY2023, three months to 2023-09-30$289.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Report this figure0.8Capital expenditure, Q4 FY2023, three months to 2023-12-31$827.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure0.4Capital expenditure, Q2 FY2024, three months to 2024-06-30$422.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$143.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2024, three months to 2024-12-31$219.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure1.2Capital expenditure, Q1 FY2025, three months to 2025-03-31$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$75.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)1.58bn, Q2 FY2025
Adaptimmune Therapeutics PLC, shares, quarterly
Line itemUnitQ3 FY20212021-09-30Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30
Diluted shares (weighted)m shares937Diluted shares (weighted), Q3 FY2021, three months to 2021-09-30936,600,648 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-08, accession 0001558370-22-016869.Report this figure940Diluted shares (weighted), Q1 FY2022, three months to 2022-03-31940,029,247 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-12, accession 0001558370-23-009595.Report this figure963Diluted shares (weighted), Q2 FY2022, three months to 2022-06-30962,794,072 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-09, accession 0001558370-23-014250.Report this figure981Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30980,791,114 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0001558370-23-018265.Report this figure1,000Diluted shares (weighted), Q1 FY2023, three months to 2023-03-311,000,276,615 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0001558370-24-008287.Report this figure1,108Diluted shares (weighted), Q2 FY2023, three months to 2023-06-301,108,166,960 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0001558370-24-011798.Report this figure1,358Diluted shares (weighted), Q3 FY2023, three months to 2023-09-301,357,849,656 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure1,451Diluted shares (weighted), Q1 FY2024, three months to 2024-03-311,451,241,661 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure1,559Diluted shares (weighted), Q2 FY2024, three months to 2024-06-301,559,183,774 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure1,535Diluted shares (weighted), Q3 FY2024, three months to 2024-09-301,534,613,977 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure1,542Diluted shares (weighted), Q1 FY2025, three months to 2025-03-311,542,159,622 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure1,585Diluted shares (weighted), Q2 FY2025, three months to 2025-06-301,584,522,868 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure

Shares outstanding: 1.59bnShares outstanding, period not labelled, at 2025-08-111,590,309,546 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure at Aug 11, 2025, from the cover of the 10-Q filed Aug 13, 2025.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.